To observe the application of phosphopropofol disodium for injection in outpatient painless diagnosis and treatment and general anesthesia

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200066678

Enrollment

Unknown

Registered

2022-12-13

Start date

2022-07-26

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intravenous anesthesia in outpatient examination or operation

Interventions

Outpatient service:Etomidate combined with propofol group (EP group):etomidate 20mg and propofol 100mg, volume ratio 1:1)

Outpatient service:Propofol disodium group(F1,F2,F3):concentration of Propofol disodium(10mg/kg,12.5mg/kg,15mg/kg)

Induction period:Propofol group:concentration of Propofol 2.0mg/kg

Induction period:Propofol disodium group(F1,F2,F3,F4):concentration of Propofol disodium(10mg/kg,12.5mg/kg,15mg/kg,20mg/kg)

Maintenance period:Propofol disodium (10-20mg/kg/h):The dosage range of phosphopropofol disodium should be determined by the patient's condition (10-20mg/kg/h).

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Patients undergoing elective short general anesthesia, ASA I-III; (2) 18-80 years old; (3) BMI 18-30 kg/m2; (4) No serious heart and lung diseases; (5) Normal communication, voluntary subjects and informed consent signed

Exclusion criteria

Exclusion criteria: (1) Serious respiratory circulatory nervous system diseases: such as severe coronary atherosclerosis, heart failure, myocardial infarction, respiratory failure and other basic diseases, heart rate 120bpm, systolic blood pressure 140mmHg; (2) mental and psychological diseases: such as schizophrenia, depression, etc.; (3) a person who has abused narcotic analgesics or sedatives, or has a history of allergy or hypersensitivity to any anesthetic, opioid or other drugs; (4) complicated with obvious liver and kidney dysfunction; (5) Predicting the possibility or history of difficult airway; (6) people with coagulation disorder; (7) Patients with a history of recovery from abnormal surgical anesthesia; (8) Pregnancy or lactation.

Design outcomes

Primary

Measure	Time frame
Blood pressure;Heart rate;oxyhemoglobin saturation;Eyelash reflection disappearance time;Time of loss of consciousness;Time of awakening;	—

Secondary

Measure	Time frame
Body moving;Postoperative pain;	—

Countries

China

Contacts

Public ContactLiu Xuesheng

The First Affiliated Hospital of Anhui Medical University

liuxuesheng@ahmu.edu.cn18655193385

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026